Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

Video

» Interview

ACC 2022: Insights from the CoreValve US Pivotal and SURTAVI Trials: Five-Year Incidence, Timing And Predictors of Hemodynamic Valve Deterioration ff Transcatheter snd Surgical Aortic Bioprostheses

April 3, 2022

Video

» Interview

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-Valve Replacement

May 4, 2022

Advertisement

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

ACC 2022: Insights from the CoreValve US Pivotal and SURTAVI Trials: Five-Year Incidence, Timing And Predictors of Hemodynamic Valve Deterioration ff Transcatheter snd Surgical Aortic Bioprostheses

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content